Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: clinical-trial pipeline
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins is the sponsor of 581 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 112 are not yet finished and 4 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Trials by phase
| Phase | Trials |
|---|---|
| Phase 2 | 230 |
| Not applicable | 148 |
| Phase 1 | 126 |
| Phase 1/2 | 44 |
| Early phase 1 | 25 |
| Phase 3 | 6 |
| Phase 2/3 | 2 |
Trials by status
| Status | Trials |
|---|---|
| Completed | 314 |
| Terminated | 122 |
| Recruiting | 65 |
| Active, not recruiting | 41 |
| Withdrawn or not authorised | 33 |
| Not yet recruiting | 6 |
Condition areas
| Area | Trials |
|---|---|
| Oncology | 545 |
| Nephrology and urology | 100 |
| Gastroenterology and liver | 85 |
| Rare and genetic diseases | 37 |
| Infectious disease and vaccines | 25 |
| Haematology | 24 |
| Musculoskeletal | 20 |
| Metabolic and endocrine (diabetes, obesity) | 16 |
| Women's health and obstetrics | 12 |
| Immunology and rheumatology | 9 |
| Dermatology | 8 |
| Cardiovascular | 6 |
Countries
| Country | Trials |
|---|---|
| United States | 555 |
| Singapore | 9 |
| Canada | 7 |
| Spain | 2 |
| Netherlands | 2 |
| Australia | 1 |
| Brazil | 1 |
| China | 1 |
| Puerto Rico | 1 |
Latest changes
| Day | Change | Trial |
|---|---|---|
| 2026-10-01 | New trial posted | GLAD-KE GLioma Biomarker and Safety Assessment During Dietary Ketone Elevation Subtitle:… |
| 2026-09-23 | New trial posted | Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinical… |
| 2026-08-28 | New trial posted | Circulating Tumor DNA (ctDNA) in High Grade Upper Tract Urothelial Cancer (UTUC) |
| 2026-08-28 | New trial posted | Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT04658147 | Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially… | Phase 1 | Active, not recruiting | United States |
| NCT00616967 | Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Bre… | Phase 2 | Active, not recruiting | United States |
| NCT04753879 | Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Canc… | Phase 2 | Active, not recruiting | United States |
| NCT06895564 | Proton SBRT for Spinal Metastasis | Not applicable | Recruiting | United States |
| NCT06315257 | A Clinical Trial to Assess PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients | Phase 1 | Recruiting | United States |
| NCT06165302 | Exercise in Prostate Cancer | Not applicable | Recruiting | United States |
| NCT05585684 | Liquid Biopsy-informed Precision Oncology Study to Evaluate Utility of Plasma Genomic Profiling for Therapy S… | Not applicable | Recruiting | United States |
| NCT01088789 | Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer | Phase 2 | Active, not recruiting | United States |
| NCT04447651 | Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM) | Not applicable | Active, not recruiting | United States |
| NCT05141513 | Intraoperative Radiation Therapy After Stereotactic Body Radiation Therapy and Chemotherapy in Treatment of P… | Phase 1 | Active, not recruiting | United States |
| NCT07129317 | Pediatric Radiation Therapy Registry | Not applicable | Recruiting | United States |
| NCT05977907 | Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN). | Phase 2 | Active, not recruiting | United States |
| NCT05917301 | Pre-operative Hypofractionated Proton Therapy | Not applicable | Recruiting | United States |
| NCT03786796 | Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations | Phase 2 | Recruiting | United States |
| NCT05121545 | Proton Pencil Beam Scanning GRID for Treatment of Bulky Tumors | Not applicable | Active, not recruiting | United States |
| NCT02989636 | Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metasta… | Phase 1 | Active, not recruiting | United States |
| NCT04386746 | Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer | Phase 2 | Active, not recruiting | United States |
| NCT04848116 | Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca | Phase 2 | Active, not recruiting | United States |
| NCT05081193 | Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metasta… | Phase 2 | Active, not recruiting | United States |
| NCT01607008 | MRI for Assessing Prostate Cancer Response | Not applicable | Active, not recruiting | United States |
| NCT06411691 | KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal… | Phase 1 | Recruiting | United States |
| NCT07062549 | Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell | Phase 1 | Recruiting | United States |
| NCT06941857 | NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Meta… | Phase 2 | Recruiting | United States |
| NCT03918252 | Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma | Phase 2 | Active, not recruiting | United States |
| NCT07142551 | Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response | Phase 2 | Recruiting | United States |
All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins clinical trials: 112 open, 8 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/sidney-kimmel-comprehensive-cancer-center-at-johns-hopkins/, data as of 2026-10-25.